Expression analysis of miRNAs regulated by EZH2 in adult T-cell leukemia

2014 Fiscal Year Final Research Report

• Project/Area Number: 25860411
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Laboratory medicine
• Research Institution: Nagasaki University
• Principal Investigator: SASAKI Daisuke 長崎大学, 病院(医学系), 技術職員 (90624784)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: ATL / EZH2 / miRNA

Outline of Final Research Achievements

MiR-181a was re-expressed in ATL cells by EZH2 inhibitor DZNep, which activated capase3/7 and induced apoptosis in ATL cells. MiR-181a has been shown to be regulated by EZH2, while miR-181a is a candidate negative regulator of BCL2 expression. We confirmed that BCL2 mRNA and protein expressions were clearly suppressed in the ATL cell lines by DZNep. DZNep inhibits cell growth that is caused BCL2 repression via miR-181a. These results strongly support the notion that miR-181a is suppressed by EZH2 and that BCL2 expression is regulated by miR-181a in ATL cells. Together, our findings indicate a unique apoptotic pathway of BCL2 suppression via miR181a and that the EZH2 inhibitor DZNep may become a novel therapeutic agent for ATL.

Free Research Field

臨床検査医学